The USFDA has granted emergency use authorization to co-packaged nirmatrelvir and ritonavir tablets to treat mild-to-moderate COVID-19 for patients with a high risk of progression to severe COVID-19, including hospitalization or death . The drug is indicated in adults and children aged ≥ 12 years and weighing at least 40 kg. It is the first FDA-approved oral antiviral drug to treat COVID-19 in adults.
The efficacy of co-packaged tablets is primarily based on the final results obtained in EPIC-HR clinical trial. EPIC-HR trial data The study proved the efficacy of oral nirmatrelvir and ritonavir co-packaged tablets for treating non-hospitalized symptomatic adults with a confirmed diagnosis of COVID-19. During 28 days of follow-up, 0.9% of patients receiving co-packaged tablets (n=977) were hospitalized due to COVID-19 or died from any cause compared to 6.5% of the patients who received…
